Factors associated with cellulitis in lymphoedema of the arm - an international cross-sectional study (LIMPRINT)

• Published in: BMC infectious diseases Vol. 24; no. 1; p. 102
• Main Authors: Burian, Ewa Anna, Franks, Peter J, Borman, Pinar, Quéré, Isabelle, Karlsmark, Tonny, Keeley, Vaughan, Sugama, Junko, Cestari, Marina, Moffatt, Christine J
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 18-01-2024; BioMed Central; BMC
• Subjects: Adult; Analysis; Arm; Body mass index; Breast cancer; Breast Neoplasms - complications; Breast-neoplasm; Cancer; Cancer therapies; Care and treatment; Cellulitis; Cellulitis - complications; Cellulitis - epidemiology; Chemotherapy; Chronic edema; Classification; Complications and side effects; Congenital diseases; Cross-Sectional Studies; Development and progression; Disease; Edema; Edema - complications; End of life; Epidemiology; Erysipelas; Female; Humans; Informed consent; Lymphatic system; Lymphedema; Lymphedema - epidemiology; Lymphedema - etiology; Lymphoedema; Medical research; Medicine, Experimental; Obesity; Patients; Questionnaires; Radiation; Risk factors; Skin; Subgroups; Surgery; Swelling; Variables; Denmark; Erysipelas; Lymphoedema; Lymphedema; Breast-neoplasm; Breast cancer; Chronic edema; Cellulitis
• ISSN: 1471-2334; 1471-2334
• DOI: 10.1186/s12879-023-08839-z

Lymphoedema is a globally neglected health care problem and a common complication following breast cancer treatment. Lymphoedema is a well-known predisposing factor for cellulitis, but few have investigated the risk factors for cellulitis in this patient cohort on an international level. The aim of this study was to identify the frequency of cellulitis in patients with lymphoedema of the arm, including potential risk factors for cellulitis.
An international, multi-centre, cross-sectional study including patients with clinically assessed arm lymphoedema. The primary outcome was the incidence of cellulitis located to the arm with lymphoedema within the last 12 months, and its potential associated risk factors. The secondary outcome was life-time prevalence of cellulitis. Adults with clinically-assessed arm lymphoedema/chronic oedema (all causes) and able to give informed consent were included. End-of-life-patients or those judged as not in the patient's best interest were excluded. Both univariable and multivariable analysis were performed.
A total of 2160 patients were included from Australia, Denmark, France, Ireland, Italy, Japan, Turkey and United Kingdom. Secondary lymphoedema was present in 98% of the patients; 95% of these were judged as related to cancer or its treatment. The lifetime prevalence of cellulitis was 22% and 1-year incidence 11%. Following multivariable analysis, factors associated with recent cellulitis were longer swelling duration and having poorly controlled lymphoedema. Compared to having lymphoedema less than 1 year, the risk increased with duration: 1-2 years (OR 2.15), 2-5 years (OR 2.86), 5-10 years (OR 3.15). Patients with well-controlled lymphoedema had a 46% lower risk of cellulitis (OR 0.54, 95% CI 0.39-0.73, p < 0.001). More advanced stages of lymphoedema were associated with cellulitis even after adjustment for swelling duration and control of swelling by logistic regression (stage II OR 5.44, stage III OR 9.13, p = 0.002), demonstrated in a subgroup analysis.
Patients with advanced arm lymphoedema are at particular risk of developing cellulitis. Prevention of lymphoedema progression is crucial. The results lend towards a positive effect of having well-treated lymphoedema on the frequency of cellulitis.